CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 129 enrolled
Drug / intervention
FAI insert +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01694186
NCT01694186Phase 3Completed

A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

EyePoint Pharmaceuticals, Inc.·interventional·Posted Sep 27, 2012·Updated Apr 2, 2021

In Brief

A Phase 3 clinical trial evaluating FAI insert and Sham injection for Non-Infectious Uveitis. Completed, enrolled 129 participants across 34 sites in 6 countries.

Detailed Summary

A study to evaluate the safety and efficacy of an FAI insert for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, Hungary, India, Israel, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 27, 2012
Enrollment StartAug 2, 2013
Primary CompletionMar 26, 2018
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 13.8 years ago

Interventions

FAI insertdrug

Sham injectiondrug